Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the...

